ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Apimeds Pharmaceuticals US (APUS)
Apimeds Pharmaceuticals US stock price today, ATLAS forecast and fair value
Healthcare · Drug Manufacturers - Specialty & Generic · NYSE
$3.05▲ +5.35%
Prices as of Oct 27, 2026 · USD
Chance of rising in 1 month
38%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Apimeds Pharmaceuticals US in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Apimeds Pharmaceuticals US
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Apimeds Pharmaceuticals US a 38% chance of finishing higher a month from now (21 trading sessions) than today: somewhat worse than a coin flip.
In half of the simulated outcomes the price ends between $1.92 and $3.66; in 9 out of 10, between $1.08 and $6.49. Estimated annual volatility is 200%.
Key numbers
- Revenue (12 months)
- $0.0M
- Return on equity
- -3.9%
- Free cash flow (12 months)
- $-6.0M
- Beta
- 0.00
What this means
ATLAS does not publish a fair value for APUS right now, but it does show its odds of rising: somewhat worse than a coin flip.
Its beta is 0.00: it tends to move less than the market.
About the company
Apimeds Pharmaceuticals US Inc. is a clinical-stage biopharmaceutical company focused on developing Apitox, a purified bee venom-based therapeutic candidate delivered intradermally.
Want to see everything about Apimeds Pharmaceuticals US?
Get started →Plans from €3.99 a month.
Frequently asked questions
What does Apimeds Pharmaceuticals US do?
Apimeds Pharmaceuticals US Inc. is a clinical-stage biopharmaceutical company focused on developing Apitox, a purified bee venom-based therapeutic candidate delivered intradermally.
What is the chance APUS goes up next month?
38%: somewhat worse than a coin flip. In half of the simulated outcomes, APUS ends the month between $1.92 and $3.66.
How volatile is APUS?
ATLAS estimates annual volatility at 200%. In a typical month, half of the outcomes end between $1.92 and $3.66.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer